Scisparc

Scisparc EBIT Growth

The Year-over-Year EBIT Growth of Scisparc (SPRC) as of Nov 7, 2026 is -19.59 %. In the previous year, Year-over-Year EBIT Growth was -26.73 % — a change of -26.72% (higher).

EBIT Growth

-19.59 %

YoY

-26.72%

Last updated:

Year-over-Year EBIT Growth of Scisparc is 2025 -19.59 % . Year-over-Year EBIT Growth of Scisparc was 2024 -26.73 % . It decreases by -26.72% higher compared to the previous year.

The Scisparc EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-68.82 USD
Jan 1, 2019
57.71 USD
Jan 1, 2020
19.84 USD
Jan 1, 2021
-75.16 USD
Jan 1, 2022
-27.95 USD
Jan 1, 2023
21.78 USD
Jan 1, 2024
-26.73 USD
Jan 1, 2025
-19.59 USD
The Scisparc EBIT Growth history
YEAREBIT GrowthYoY
-19.59 %-26.72%
-26.73 %-222.75%
21.78 %-177.91%
-27.95 %-62.82%
-75.16 %-478.84%
19.84 %-65.62%
57.71 %-183.86%
-68.82 %-63.42%
-188.12 %-965.19%
21.74 %-149.94%
-43.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Year-over-Year EBIT Growth of Scisparc is -19.59 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Scisparc since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Scisparc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Scisparc

All Key Metrics — Scisparc